Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

Table 3 Univariate subgroups analysis of progression-free survival

	FOLFOX-4			TOPOTECAN
	No. patients	No. events	Median PFS (95% CI)	No. patients	No. events	Median PFS (95% CI)	P
Site of metastasis
Only abdominal	11	10	2.8 (0.6–5.6)	20	20	2.7 (1.1–3.6)	0.617
Abdominal+extra-abdominal	18	18	2.8 (1.7–7.0)	6	6	5.0 (0.9–10.7)	0.941
P			0.544			0.211
Lines of previous treatments
≤ 4	15	15	2.6 (0.6–4.6)	20	20	3.2 (1.6–5.4)	0.948
> 4	14	13	2.8 (1.7–8.4)	6	6	2.2 (0.7–4.9)	0.124
P			0.401			0.054
Baseline NLR
< 3	13	12	3.0 (2.4–18.5)	20	20	2.9 (1.6–5.1)	0.142
≥ 3	15	15	1.9 (0.7–4.6)	5	5	2.5 (1.0–6.6)	0.690
P			0.075			0.388
Baseline PLR
< 210	13	12	2.9 (0.7–18.5)	18	18	2.9 (1.6–5.1)	0.235
≥ 210	15	15	2.5 (0.9–4.6)	7	7	2.5 (0.9–3.5)	0.539
P			0.177			0.154

Abbreviation. FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil, CI confidence interval, NLR neutrophil-to-lymphocyte ratio, PFS progression-free survival, PLR platelet-to-lymphocyte ratio

ISSN: 1471-2407